Combinatorial treatment protocols may also include blocking oncogenic signaling from mutant KRAS and from other stromal constituents, correcting aberrant epigenomes, eliminating extracellular vesicles that typically promote carcinogenesis, diminishing the EMT to hinder the metastasis and acquisition of cancer stem-like cells, as well as boosting the infiltration of antitumor immune cells [260] (partly exemplified in Table 1). Here, KRAS is linked to cancer.